Program
garetosmab
Also written as “Garetosmab”, “REGN2477” and “REGN2477+REGN1033”.
Its studies are mostly in Myositis Ossificans · Obesity · Ossification, Heterotopic · Myositis, Inclusion Body, led by Regeneron Pharmaceuticals.
Furthest: phase 3, since Sep 30, 20209 company-led studies, 2 open or runningNext primary completion: Jul 8, 2030 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 92 open or running | phase 3since Sep 30, 2020 | Aug 12, 2016 | Jul 8, 2030phase 3 · NCT07559513 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 12, 2016First study: phase 1 study in Healthy VolunteersFirst studyNCT02870400 · 41 enrolled · Belgium
- Oct 19, 2016Phase 1 study in Healthy VolunteersNCT02943239 · 82 enrolled · New Zealand
- Jun 13, 2017Phase 2 study in Myositis OssificansNCT03188666 · 44 enrolled · United States, Canada, France and more
- Oct 15, 2018Phase 2 study in Myositis, Inclusion BodyNCT03710941
- Sep 30, 2020Phase 3 study in Ossification, HeterotopicNCT04577820
- May 4, 2022Phase 3 study in Myositis OssificansNCT05394116 · 63 enrolled · United States, Australia, Brazil and more
- Mar 1, 2024Phase 2 study in ObesityNCT06299098 · 1,005 enrolled · United States, Puerto Rico
- May 6, 2025Phase 1 study in ObesityNCT06970405
- Apr 22, 2026Phase 3 study in Myositis OssificansNCT07559513 · 18 planned
- Oct 8, 2026Primary completion moved from 2028-12-10 to 2030-07-08Date moved laterphase 3 · +19 months · NCT07559513
Ahead
- Jul 8, 2030Primary completion: phase 3 study in Myositis OssificansNCT07559513
TargetBeta
INHBA →read by rule
“Inhibin beta A chain inhibitor”ChEMBL 37, by rule
Other programs on INHBA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotaterceptrule | Merck | phase 4 | 26 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07559513Myositis Ossificans | 3 | Not yet recruiting | Jul 8, 2030 | 18 |
| NCT06970405Obesity | 1 | Withdrawn | Jun 8, 2026 | 0 |
| NCT06299098Obesity · United States, Puerto Rico | 2 | Completed | Jun 16, 2026 | 1,005 |
| NCT05394116Myositis Ossificans · United States, Australia, Brazil and more | 3 | Active, not recruiting | Jul 17, 2025 | 63 |
| NCT04577820Ossification, Heterotopic | 3 | Withdrawn | Mar 1, 2022 | 0 |
| NCT03710941Myositis, Inclusion Body | 2 | Withdrawn | Aug 27, 2020 | 0 |
| NCT03188666Myositis Ossificans · United States, Canada, France and more | 2 | Completed | Sep 16, 2019 | 44 |
| NCT02943239Healthy Volunteers · New Zealand | 1 | Completed | Apr 30, 2019 | 82 |
| NCT02870400Healthy Volunteers · Belgium | 1 | Completed | Jan 12, 2017 | 41 |
How it is read
Names in the registry
- “Garetosmab”, 3 entries
- “REGN2477”, 3 entries
- “garetosmab”, 2 entries
- “REGN2477+REGN1033”, 1 entry
Conditions, from the studies’ own filings
- Myositis Ossificans, 3 studies
- Obesity, 2 studies
- Ossification, Heterotopic, 1 study
- Myositis, Inclusion Body, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.